Phase 4 N=15 Paroxetine/Bupropion in Depression With Suicide Attempt or Thoughts: fMRI Study
Depression · Suicidal Ideation
Primary: Percent Change in Contrast of Parameter Estimates (COPE) — 0.29; -2.12; -1.19; -1.33 Percentage change
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=204 Phase 2, Double-Blind, Placebo-Controlled Trial of Bupropion for Methamphetamine Dependence
Methamphetamine Dependence
Primary: Number of Subjects Showing Abstinence — 14; 20 Participants
Phase 2 N=52 Improving Learning-based Treatment of Cocaine Dependence With Medication
COCAINE-RELATED DISORDERS
Primary: Urinalysis Benzoylecgonine (Cocaine Metabolite)(ng/ml) — 36.7; 32.4 ng/ml
Phase 3 N=882 Study to Evaluate Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Vaccine (Zoster Vaccine Live, V211) Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated) in Participants ≥50 Years of Age (V211-062)
Herpes Zoster
Primary: Geometric Mean Titer (GMT) of Varicella-zoster Virus (VZV) Glycoprotein Enzyme-linked Immunosorbent Assay (gpELISA) Antibody — 206.0; 230.5; 395.6; 482.0 gpELISA…
Phase 3 N=147 Use of Artefill® for Moderate to Severe Atrophic Acne Scar Correction
Atrophic Acne Scar
Primary: ASRS Responder Rate at 6 Months — 32.4; 67.4 percentage of participants
N/A N=385 Advance Planning for Home Services for Seniors
Alzheimers, Falls, Aging in Place
Primary: Planning Behavior Score at 1-month — 16.97; 16.80; 17.19; 15.88 units on a scale — p=0.0054
N/A N=12 Insulin Resistance in Patients With Mood Disorder
Depression · Bipolar Disorder · Insulin Resistance
Primary: Hamilton Depression Rating Scale (HDRS-21) — 19.9; 13.0 units on a scale
Phase 2 N=216 Evaluation of Dose Response Relationship, Safety and Efficacy of GSK1278863 in Hemodialysis-dependent Subjects With Chronic Kidney Disease Associated Anemia
Anaemia
Primary: Change From Baseline in Hemoglobin (Hgb) at Week 4 — -0.64; -0.24; 0.08; 0.42 grams (g)/deciliter (dL)
Phase 3 N=211 Study to Evaluate the Efficacy and Safety of Benralizumab in Adult Patients With Mild to Moderate Persistent Asthma
Asthma
Primary: Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) (L) at Week 12 — 2.248; 2.246; 2.310; 2.261 Litre — p=0.040
Phase 2 N=62 A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas
Neurofibromatosis Type 1
Primary: Time to Disease Progression Based on Volumetric MRI — 15.4 Months
Phase 3 N=6 Collagenase Option for Reduction of Dupuytren's Contracture in Japan
Dupuytren's Contracture
Primary: The Percentage of Participants That Were Successfully Treated With a "Successful Reduction in Contracture to 5°or Less" — 86 % Participants
Phase 2 N=61 Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene Laherparepvec
Melanoma
Primary: Percentage of Participants With Detectable Talimogene Laherparepvec Deoxyribonucleic Acid (DNA) During the First Three Cycles — 98.3; 100.0; 97.5; 31.7 percentage of…
N/A N=26 Vitamin D Supplementation Reduces Renin-Angiotensin System Activity in Obesity
Obesity · Vitamin D Deficiency · Hypertension
Primary: The Change in the Mean Arterial Blood Pressure in Response to an Infusion of Angiotensin II — 1.97 mmHg — p=<0.05
Phase 2 N=20 PCI-24781 in Combination With Doxorubicin to Treat Sarcoma
Sarcoma
Primary: Maximum Tolerated Dose — 15; 45 mg/m2
Phase 4 N=376 A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB)
Overactive Bladder (OAB)
Primary: Participants Tolerability Assessed by the Medication Tolerability Scale of the Overactive Bladder-Satisfaction (OAB-S) Questionnaire at the End of Treatment (EOT)…